Stocks
Evolent Health Financial Statements (EVH) |
||||||||||
| Evolent Healthsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 26.02.2021 | 24.02.2022 | 24.02.2023 | 23.02.2024 | 10.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 846.4 | 1 022 | 908.0 | 1 352 | 1 964 | 2 176 | |||
| Operating Income, bln rub | -120.4 | -37.9 | 30.2 | -59.8 | -71.2 | -55.0 | ||||
| EBITDA, bln rub | ? | -65.5 | 23.6 | 90.3 | 7.36 | 46.4 | 119.1 | |||
| Net profit, bln rub | ? | -305.6 | -334.2 | -30.3 | -18.7 | -113.0 | -110.3 | |||
| OCF, bln rub | ? | -42.6 | -16.2 | 38.7 | -11.6 | 142.6 | 155.5 | |||
| CAPEX, bln rub | ? | 35.5 | 29.5 | 25.0 | 38.4 | 28.7 | 25.0 | |||
| FCF, bln rub | ? | -78.2 | -45.7 | 13.8 | -49.9 | 113.8 | 130.4 | |||
| Dividend payout, bln rub | 0.000 | 20.0 | 1.30 | 14.9 | 18.8 | 20.2 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18.3% | ||||
| OPEX, bln rub | 453.7 | 372.0 | 279.5 | 336.5 | 481.5 | 431.3 | ||||
| Cost of production, bln rub | 513.1 | 701.4 | 657.6 | 1 035 | 1 503 | 1 758 | ||||
| R&D, bln rub | 19.8 | 15.1 | 15.5 | 27.0 | 26.7 | 26.3 | ||||
| Interest expenses, bln rub | 14.5 | 28.3 | 25.4 | 15.6 | 54.2 | 47.3 | ||||
| Assets, bln rub | 1 498 | 1 370 | 1 419 | 1 817 | 2 680 | 2 644 | ||||
| Net Assets, bln rub | ? | 922.4 | 619.6 | 693.6 | 859.4 | 1 068 | 1 048 | |||
| Debt, bln rub | 368.8 | 359.8 | 280.5 | 476.1 | 644.8 | 824.4 | ||||
| Cash, bln rub | 101.0 | 340.5 | 266.3 | 188.2 | 192.8 | 216.7 | ||||
| Net debt, bln rub | 267.8 | 19.3 | 14.2 | 287.9 | 452.0 | 607.6 | ||||
| Ordinary share price, rub | 9.05 | 16.0 | 27.7 | 28.1 | 33.0 | 24.0 | ||||
| Number of ordinary shares, mln | 82.4 | 84.9 | 86.1 | 93.7 | 111.3 | 114.1 | ||||
| Market cap, bln rub | 745 | 1 361 | 2 381 | 2 631 | 3 675 | 2 736 | ||||
| EV, bln rub | ? | 1 013 | 1 381 | 2 396 | 2 919 | 4 127 | 3 344 | |||
| Book value, bln rub | 42 | -3 | -12 | -306 | -801 | -800 | ||||
| EPS, rub | ? | -3.71 | -3.94 | -0.35 | -0.20 | -1.02 | -0.97 | |||
| FCF/share, rub | -0.95 | -0.54 | 0.16 | -0.53 | 1.02 | 1.14 | ||||
| BV/share, rub | 0.51 | -0.04 | -0.14 | -3.27 | -7.20 | -7.01 | ||||
| EBITDA margin, % | ? | -7.73% | 2.31% | 9.94% | 0.54% | 2.36% | 5.48% | |||
| Net margin, % | ? | -36.1% | -32.7% | -3.34% | -1.38% | -5.76% | -5.07% | |||
| FCF yield, % | ? | -10.5% | -3.36% | 0.58% | -1.90% | 3.10% | 4.77% | |||
| ROE, % | ? | -33.1% | -53.9% | -4.37% | -2.18% | -10.6% | -10.5% | |||
| ROA, % | ? | -20.4% | -24.4% | -2.13% | -1.03% | -4.22% | -4.17% | |||
| P/E | ? | -2.44 | -4.07 | -78.6 | -140.7 | -32.5 | -24.8 | |||
| P/FCF | -9.53 | -29.8 | 173.0 | -52.7 | 32.3 | 21.0 | ||||
| P/S | ? | 0.88 | 1.33 | 2.62 | 1.95 | 1.87 | 1.26 | |||
| P/BV | ? | 17.8 | -424.6 | -191.3 | -8.59 | -4.59 | -3.42 | |||
| EV/EBITDA | ? | -15.5 | 58.5 | 26.5 | 396.6 | 89.0 | 28.1 | |||
| Debt/EBITDA | -4.09 | 0.82 | 0.16 | 39.1 | 9.74 | 5.10 | ||||
| R&D/CAPEX, % | 55.7% | 51.2% | 62.0% | 70.4% | 92.9% | 105.0% | ||||
| CAPEX/Revenue, % | 4.20% | 2.88% | 2.75% | 2.84% | 1.46% | 1.15% | ||||
| Evolent Health shareholders | ||||||||||
